ArticleHepatitis monthly2012
Hepatocellular carcinoma in pakistan: where do we stand?
Article in Hepatitis monthly, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Molecular characterization of plasma virome of hepatocellular carcinoma (HCC) patients.AMB Express · 2024Article
- Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review.World journal of gastrointestinal oncology · 2024Article
- Portal vein thrombosis in patients with hepatocellular carcinoma and early cirrhosis-prevalence and risk factors.Ecancermedicalscience · 2023Article
- Review
- Review
- Screening ofACS omega · 2022Article
- Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.The lancet. Gastroenterology & hepatology · 2020Review
- The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease.Hepatitis monthly · 2016Article
- Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective.Gastroenterology research and practice · 2016Review
- The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial.Hepatitis monthly · 2013Article
- Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population.Hepatitis monthly · 2013Article
- Frequency ofEuroasian journal of hepato-gastroenterologyArticle
- Epidemiology of Viral Hepatitis and Liver Diseases in Pakistan.Euroasian journal of hepato-gastroenterologyReview
- Detection of Primary Hepatocellular Carcinoma onEuroasian journal of hepato-gastroenterologyArticle
- Viral Hepatitis in Pakistan: Past, Present, and Future.Euroasian journal of hepato-gastroenterologyReview
- Hepatocellular Carcinoma (HCC), Where do we stand? Current situation.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextFrom the 1970s till the mid 1990s, hepatitis B was the most common etiological factor for hepatocellular carcinoma (HCC) in Pakistan. Afterwards, a shift in HCC etiology was observed with a steady rise in hepatitis C virus (HCV) related HCC cases. HCV-3a, which is the most prevalent genotype, is also most frequent in HCV related HCC. There was an increase in the proportion of non-B non-C (NBNC) HCC cases as well, which might be attributed to an increase in non-alcoholic fatty liver disease. EVIDENCE ACQUISITION: The age-standardized rate for HCC is 7.64/100 000 in males and 2.8/100 000 in females. Male to female ratio is 3.6:1. Usual age of presentation is in the fifth and sixth decade. Most patients present with advanced disease, as they are not in a regular surveillance program. This is more so for patients with NBNC chronic liver disease. As many sonologists in Pakistan are practicing without sufficient training to pick up early lesions, alpha-fetoprotein is still recommended to compliment ultrasound in the surveillance of HCC.
resultsMajority of HCC patients present with nonresectable disease. Interventions such as transarterial chemoembolization, radiofrequency ablation, resection and chemotherapy including sorafenib are available in selected centers. Pakistan appears to be in an area of intermediate endemicity for HCC. There is a need for population based epidemiological studies to estimate the exact disease burden.
conclusionsMeasures to prevent the spread of hepatitis C and B can slow down the epidemic rise in the incidence of HCC in the coming decades. There is a need to implement a proper surveillance program to identify HCC cases at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.